SOURCE: Paragon Financial Limited

Paragon Financial Limited

October 26, 2011 08:16 ET

Positive Test Results and Acquisitions Drive Shares of Exelixis and Anadys Higher

The Paragon Report Provides Equity Research on Exelixis & Anadys Pharmaceuticals

NEW YORK, NY--(Marketwire - Oct 26, 2011) - Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Exelixis, Inc. (NASDAQ: EXEL) and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS). Access to the full company reports can be found at:

www.paragonreport.com/EXEL
www.paragonreport.com/ANDS

While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Earlier this week share of Exelixis skyrocketed after the company said its most advanced experimental drug more than doubled the amount of survival time of patients with a type of thyroid cancer. Exelixis said it will meet the Food and Drug Administration, and will ask if it can submit its application for approval of cabozantinib piece-by-piece instead of waiting to file its application all at once. The company plans to finish its application in the first half of 2012. The FDA has agreed to approve cabozantinib if data shows it improves patients' survival.

Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing novel medicines for the treatment of hepatitis C in the United States. Shares of the company skyrocketed this month after Swiss drugmaker Roche Holding AG announced that it is paying $230 million to take over Anadys.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer